Table 3 Sensitivity analysis between A) inflammatory indices and albuminuria, B) inflammatory indices and macroalbuminuria.

From: Association between inflammation indicators and albuminuria in US adults: a cross-sectional study

A) Sensitivity analysis between inflammatory indices and albuminuria.

Index

Characteristic

Model1

 

Model2

 

Model3

 

OR (95% CI)

p-value

OR (95% CI)

p-value

OR (95% CI)

p-value

Ln-CLR

Continuous

1.33 (1.27 to 1.38)

<0.001

1.23 (1.18 to 1.29)

<0.001

1.10 (1.04 to 1.16)

<0.001

Q1

Reference

 

Reference

 

Reference

 

Q2

1.35 (1.15 to 1.59)

<0.001

1.14 (0.98 to 1.32)

0.091

1.03 (0.85 to 1.23)

0.78

Q3

1.77 (1.50 to 2.10)

<0.001

1.41 (1.20 to 1.66)

<0.001

1.13 (0.94 to 1.36)

0.18

Q4

2.44 (2.08 to 2.86)

<0.001

1.86 (1.59 to 2.18)

<0.001

1.24 (1.02 to 1.50)

0.033

Ln-IBI

Continuous

1.32 (1.26 to 1.37)

<0.001

1.25 (1.20 to 1.31)

<0.001

1.13 (1.08 to 1.19)

<0.001

Q1

Reference

 

Reference

 

Reference

 

Q2

1.49 (1.28 to 1.75)

<0.001

1.28 (1.10 to 1.49)

0.002

1.16 (0.97 to 1.38)

0.1

Q3

1.91 (1.59 to 2.30)

<0.001

1.55 (1.29 to 1.87)

<0.001

1.28 (1.05 to 1.57)

0.015

Q4

2.67 (2.28 to 3.12)

<0.001

2.16 (1.85 to 2.52)

<0.001

1.48 (1.25 to 1.75)

<0.001

Ln-NAR

Continuous

2.23 (1.91 to 2.60)

<0.001

2.38 (2.04 to 2.78)

<0.001

1.82 (1.50 to 2.20)

<0.001

Q1

Reference

 

Reference

 

Reference

 

Q2

1.27 (1.08 to 1.49)

0.006

1.27 (1.08 to 1.50)

0.006

1.07 (0.89 to 1.30)

0.46

Q3

1.40 (1.15 to 1.69)

<0.001

1.41 (1.17 to 1.70)

<0.001

1.23 (1.01 to 1.49)

0.044

Q4

2.14 (1.81 to 2.53)

<0.001

2.25 (1.90 to 2.67)

<0.001

1.72 (1.42 to 2.07)

<0.001

B) Sensitivity analysis between inflammatory indices and macroalbuminuria.

Index

Characteristic

Model1

 

Model2

 

Model3

 

OR (95% CI)

p-value

OR (95% CI)

p-value

OR (95% CI)

p-value

Ln-CLR

Continuous

1.49 (1.33 to 1.66)

<0.001

1.39 (1.23 to 1.57)

<0.001

1.07 (0.94 to 1.22)

0.3

Q1

Reference

 

Reference

 

Reference

 

Q2

1.59 (0.96 to 2.64)

0.073

1.31 (0.79 to 2.15)

0.29

0.94 (0.51 to 1.71)

0.82

Q3

2.66 (1.66 to 4.25)

<0.001

2.09 (1.31 to 3.35)

0.003

1.39 (0.83 to 2.33)

0.2

Q4

3.91 (2.46 to 6.21)

<0.001

2.93 (1.82 to 4.71)

<0.001

1.19 (0.70 to 2.03)

0.051

Ln-IBI

Continuous

1.50 (1.35 to 1.65)

<0.001

1.44 (1.29 to 1.61)

<0.001

1.14 (1.01 to 1.29)

0.039

Q1

Reference

 

Reference

 

Reference

 

Q2

1.68 (1.01 to 2.80)

0.044

1.43 (0.86 to 2.36)

0.16

1.10 (0.63 to 1.91)

0.73

Q3

2.42 (1.50 to 3.92)

<0.001

1.95 (1.22 to 3.11)

0.006

1.32 (0.77 to 2.26)

0.3

Q4

4.89 (3.10 to 7.71)

<0.001

3.93 (2.46 to 6.29)

<0.001

1.65 (0.99 to 2.75)

0.053

Ln-NAR

Continuous

5.47 (3.53 to 8.48)

<0.001

5.89 (3.72 to 9.34)

<0.001

2.56 (1.52 to 4.33)

<0.001

Q1

Reference

 

Reference

 

Reference

 

Q2

1.28 (0.83 to 1.98)

0.25

1.35 (0.87 to 2.11)

0.18

1.05 (0.63 to 1.75)

0.85

Q3

1.95 (1.26 to 3.02)

0.003

2.11 (1.34 to 3.32)

0.002

1.67 (0.98 to 2.83)

0.058

Q4

4.00 (2.58 to 6.20)

<0.001

4.40 (2.77 to 6.98)

<0.001

2.15 (1.19 to 3.87)

0.012

  1. Model 1: no covariates were adjusted. Model 2: gender, age, race and education level were adjusted. Model 3: gender, age, race, education level, PIR, BMI, smoking status, drinking status, diabetes, hypertension, albumin, serum uric acid, TC, HDL-C, ALT, AST and eGFR were adjusted.
Back to article page